IL-2 and IFN-α with 5-FU vs Tamoxifen in Kidney Cancer
Author Information
Author(s): Atzpodien J, Kirchner H, Illiger H J, Metzner B, Ukena D, Schott H, Funke P J, Gramatzki M, Jürgenson S von, Wandert T, Patzelt T, Reitz M, D. G. C. I. N.
Primary Institution: Medizinische Hochschule Hannover
Hypothesis
Does the combination of IL-2, IFN-α, and 5-FU provide better outcomes than tamoxifen in metastatic renal cell carcinoma?
Conclusion
The combination therapy showed significant therapeutic efficacy compared to tamoxifen in patients with progressive renal cell carcinoma.
Supporting Evidence
- 39.1% of patients treated with the new therapy had an objective response.
- 17.1% had complete responses and 21.9% had partial responses.
- Overall survival was 24 months for the new therapy group compared to 13 months for the tamoxifen group.
Takeaway
Doctors tested a new treatment for kidney cancer and found it worked better than an older medicine.
Methodology
A randomized clinical trial comparing two treatment regimens in patients with metastatic renal cell carcinoma.
Limitations
The study may have limitations related to sample size and the specific patient population.
Participant Demographics
Patients with progressive metastatic renal cell carcinoma.
Statistical Information
Confidence Interval
95% CI, 24.2–55.5
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website